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 Abstract 
Background: Strong evidence on the long term safety and efficacy of different types 
of anticoagulants would help clinicians to prevent thromboembolic events among 
Atrial Fibrillation (AF) patients while minimising the risk of haemorrhages. 
Aim: To estimate the risk of thromboembolic and haemorrhagic events for AF 
patients on antiplatelets or anticoagulants. 
Design and setting: Cohort study. Routinely collected primary and secondary care 
clinical data from AF patients, aged ≥18, and indication to receive anticoagulation, 
prior to April 2012, were used 
Methods: The risk of Ischaemic Stroke or Transient Ischaemic Attack (TIA), 
Coronary Heart Disease (CHD), Peripheral Artery Disease, or Gastrointestinal (GI) 
haemorrhage, between April 2012 and April 2017, was estimated using multivariate 
Cox regression models for patients on antiplatelets only, a combination of 
antiplatelets and Vitamin K Antagonists (VKAs), or Novel Oral Anticoagulants 
(NOACs), compared to those on VKAs only.  
Results: Compared to VKAs, antiplatelets were associated with a higher risk of stroke 
or TIA, Hazard Ratio (HR): 1.51, 95% Confidence interval (CI): (1.09-2.09), and GI 
haemorrhage, HR (95% CI): 1.79 (1.01-3.18). The risk of thromboembolic and 
haemorrhagic events was similar for those on a combination of antiplatelets and 
VKAs, or those on VKAs only. The risk was also similar for those on NOACs or 
VKAs, except for CHD, where it was increased for patients on NOACs, HR (95% 
CI): 2.07 (1.35-3.19).  
Conclusion: anticoagulants are associated with lower risk of thromboembolic and 
haemorrhagic events among AF patients, than antiplatelets. More research is required 
on the risk associated with VKAs or NOACs. 
 Key Words: Atrial Fibrillation, Primary Health Care, Anticoagulants, Stroke, 
Gastrointestinal Haemorrhage, Myocardial Ischaemia. 
 
 How this fits in: 
A number of studies have compared the safety and efficacy of different anticoagulants 
in AF patients, most of them have focused on the prevention of strokes, with other 
potential outcomes receiving less attention, and have reported conflicting results on 
the association with different thromboembolic and haemorrhagic events.  
In our study, compared to Vitamin K antagonists (VKA), antiplatelets were associated 
with a higher risk of TIA or stroke, and gastroentitestinal haemorrhage; the risk was 
similar for those on a combination of antiplatelets and VKAs; the risk was also similar 
for those on Novel Oral Anticoagulants, except for coronary heart disease, where 
patients had an increased risk.  
This evidence suggests lower thromboembolic and haemorrhagic risk of 
anticoagulants over antiplatelets but does not support prioritizing VKAs or NOACs. 
More research is required on the risk and efficacy of VKAs and NOACs. 
 
 
 
 
 
 
 
 
 
 Introduction 
Atrial fibrillation (AF) is a leading cause of morbidity and mortality, with five million 
incident cases a year, and an increasing prevalence, worldwide.1 It is strongly 
associated with a higher risk of acute cardiovascular events, increased mortality, 
higher medical costs and a reduced quality of life.2-4 Treatment with anticoagulation is 
key to prevent thromboembolic events in AF patients.5  Traditionally Vitamin K 
antagonists (VKAs) have been the first line anticoagulant agents for these patients. 
However, since 2010 the novel oral anticoagulants (NOACs), have become available 
to manage AF.6  
A number of studies have compared the safety and efficacy of NOACs versus VKAs, 
most of them have focused on the prevention of strokes, with other potential outcomes 
receiving less attention, and have reported conflicting results on the association with 
different thromboembolic and haemorrhagic events.3, 6-11 Factors associated with the 
choice of anticoagulation, such as socioeconomic status, or estimates or 
thromboembolic events, have not always been acknowledged in previous studies.12 
There are also some concerns regarding the safety of NOACs in real world settings, 
where they are prescribed to a broad range of patients, particularly with respect to 
bleeding as there is a limited choice of expensive antidotes.13, 14 
Despite the better safety and efficacy of anticoagulants over antiplatelets in the 
prevention of thromboembolic events among those with AF, a significant proportion 
of patients are still on antiplatelets only. 
Therefore the evidence on the long term safety and efficacy of anticoagulation is still 
limited and not fully applied in clinical practice. Stronger evidence on the effects of 
different types of anticoagulants and antiplatelets would help clinicians to prevent 
thromboembolic events while minimising the risk of haemorrhagic episodes among 
 AF patients. 
This study tests the hypothesis that risk of thromboembolic and haemorrhagic events 
varies for those treated with different anticoagulants or antiplatelets, and that the 
estimated thromboembolic risk, and socioeconomic status, may affect these 
differences. The risk of ischaemic stroke (IS) or transient ischaemic attack (TIA), 
CHD, PAD, and gatrointestinal (GI) haemorrhage, is estimated over a period of five 
years, for patients with AF treated with antiplatelets, a combination of antiplatelets 
and VKAs, or NOACs, compared to those taking only VKAs.3, 15  
 
Methods 
The study conformed to the STROBE study design recommendations.16 
Prospective cohort study, including patients aged ≥18, with at least one year 
registration in the area of study, with a diagnosis of AF, and a risk of thromboembolic 
events high enough to have indication to receive anticoagulation17 (CHA2DS2VASc18 
score ≥2), prior to the 1st of April 2012.  
All data were collected from routinely recorded clinical notes from the East London 
Primary care database, that has records of all patients registered in 140 practices in 
three contiguous boroughs of London, and The Secondary Uses Service, that has 
clinical data from the hospitals in those same areas. Primary and secondary care 
records data were linked using pseudoanonymised identifiers.  Sociodemographic 
variables included age, and gender. The English Index of Deprivation was recorded as 
a measure of socioeconomic status.19  Clinical data included  risk of thromboembolic 
outcomes, measured with the CHA2DS2VASc score,18 and the first diagnoses 
between 1st April 2012 and 1st April 2017 of TIA or IS, CHD, PAD, and GI 
haemorrhage. When clinical data were collected from primary care they were defined 
 using the read codes from the Quality and Outcomes Framework ruleset entered by 
doctors in the medical records.20 Clinical data from secondary care were defined using 
the tenth version of the International Classification of Diseases.21 Data on treatments 
were extracted for each drug according to their classification as antiplatelets, NOACs 
or VKAs in the British National Formulary.22 Data on each treatment category were 
taken from the earliest prescription of each treatment category, or from the 1st of April 
2012, if the earliest prescription was before that date.  
The risk of having TIA or IS, CHD, PAD, or GI haemorrhage, between 1st of April 
2012 and the 1st of April 2017, was estimated using Cox regression models for those 
who were on antiplatelets only during the follow up, a combination of antiplatelets 
and VKAs, or NOACs, compared to those who were only VKAs. All models were 
first adjusted for age and gender, and later for variables that can affect choice of 
anticoagulation and risk of different outcomes: socioeconomic status, and risk for 
thromboembolic events (CHA2DS2VASc score).12, 18, 23, 24 
Patients were censored when they left the area of study (moving somewhere else or 
dying), they experienced their first outcome, or they stopped the treatment of interest 
(last prescription was issued). The risk for different outcomes was estimated 
independently, with a different model. The whole sample was treated as a single 
cohort, as patients were all living in the same area of London, where there is free 
access to health care for everyone, health care is standardized, and all patients were 
treated as independent within the cohort.  
 
Results 
A total of 4943 AF patients were initially identified in the database. 465 of them were 
excluded, as they had got AF resolved before the beginning of the study, and 607 
 because their CHA2DS2VASc score was<2. Finally, 3871 patients with AF diagnosed 
before 2012, with mean age 76.99 (SD: 10.44), 1925 (49.7%) of them women, were 
included in the study. All of them had their risk for thromboembolic outcomes 
measured and the median and interquartile range CHA2DS2VASc score was 4 (3-5). 
The socioeconomic status was measured in 3646 of them and their median and 
interquartile range English Index of Deprivation score was 42.7 (36.6-49.2)  
The description of participants who took each drug during the study period, and the 
outcomes they had, are presented in table one. 
Patients who took only antiplatelets had higher risk of having a TIA or IS, and GI 
haemorrhages, than those on VKAs. The risk of having all outcomes was similar for 
those on VKAs and antiplatelets, than for those on VKAs only. Patients on NOACs 
had higher risk of having CHD than those on VKAs, and similar risk for all other 
outcomes. These associations did not change when models were further adjusted for 
CHA2DS2VAc and socioeconomic status (table two).  
 
Discussion 
Summary:  
In our study, AF patients who take only antiplatelets have higher risk of 
thromboembolic and haemorrhagic events than those on VKAs, those on a 
combination of VKAs and antiplatelets have similar risk than those on VKAs only, 
and finally those on NOACs had also similar risk, except for CHD where the risk is 
increased, compared to those on VKAs. The socioeconomic status and risk for 
thromboembolic outcomes, make no difference to these associations. 
Strengths and limitations: 
An important limitation for our study is the lack of information on patient adherence 
 to their prescribed drugs, which may have lead to a possible misclassifications of 
exposure. The east London database captures all prescriptions issued by the general 
practice team and there is evidence showing that 97% of cardiovascular medications 
dispensed as prescribed However, non-adherence to dispensed drugs may have still 
contributed to an underestimation of both the efficacy of the drugs in the prevention 
of IS, and the risk for haemorrhagic outcomes. It should be noted that the absence of 
adherence data is a limitation that affects most observational studies using large 
clinical databases.25 The low number of outcomes registered in some treatment 
categories is one of the limitations of our study. While the sample size was reasonable 
large, some interesting clinical events such as haemorrhagic strokes could not be 
included in the analysis, and others such as TIA and ischaemic strokes had to be 
categorized together, due to the low number of cases in the dataset. Future studies 
with larger sample size could investigate these outcomes separately, and how are they 
are affected by comorbidities and other medication.  
The long follow up and the adjustment for factors associated with choice of 
anticoagulation and thromboembolic events, is a strength of this study.12, 18, 23, 24 
Furthermore all data were entered into the medical record prospectively, minimizing 
the risk of recall bias or inaccurate self-report. We also applied a minimum of 
exclusion criteria to describe real-world effects with maximum external validity. The 
use of structured data entry templates, and clinical facilitation in the east London 
practices studied, enabled routine entry of high quality data using agreed code sets for 
recording atrial fibrillation and CVR factors.  Finally, the diagnoses of atrial 
fibrillation, CVR factors, and the medication prescribed is  routinely reviewed by 
local clinicians as part of their national Quality and Outcome Framework audit returns 
which provides further validation of data quality..  
  
Comparison with existing literature: 
The similar risk of TIA or IS for those on NOACs and VKAs is consistent with the 
results of two systematic reviews of observational studies and a recent large cohort 
study. 6, 10, 25 However, another two systematic reviews of observational studies have 
reported a lower risk of IS for those on Rivaroxaban compared to VKAs.9, 26 The 
results of our study, and part of the previous observational literature, differs from the 
results of randomised controlled trials, where NOACs are associated with lower risk 
of IS and CHD than warfarin.6, 10, 27 This may be because in most trials the 
participants are different from our real-world AF population.  
The higher risk of CHD among those on NOACs, observed in our study, differs from 
the results of a systematic review of observational studies that reported similar risk for 
both therapies.10 However, two recent observational studies have reported a higher 
risk of CHD for those on NOACs than for those on VKAs.8, 28 The higher risk of 
CHD for those on NOACs may be explained by the low dose of NOACs that many 
AF patients receive to reduce the risk of bleeding, and the intensive follow up from 
anticoagulation clinics, that those on VKAs, but not those on NOACs, receive.8 
An increased risk of GI bleed has been reported by systematic reviews of 
observational studies, and a recent large cohort study, for those on rivaroxaban,9, 10, 25 
or dabigatran6, 10 compared to patients on VKAs. However, apixaban was associated 
with a lower risk of major bleed than warfarin.25 No differences in risk of GI bleed 
were observed in our study for any treatment category. This can be because of the low 
number of patients with GI haemorrhages included in the cohort, the analysis of all 
NOACs as a single category, or the genuine absence of association in our study 
population. 
  
Implications for clinical practice and future research: 
The conflicting results of our study, and the previous literature, make difficult to 
produce definitive clinical recommendations and would support the current guidelines 
that recommend that treatment with anticoagulation should be individualized 
depending on patients’ adherence to prescribed therapy, comorbidities, other 
prescribed drugs, and lifestyle factors.17, 29, 30 The available evidence suggests better 
safety and efficacy of anticoagulants over antiplatelets but does not support 
prioritizing VKAs or NOACs. 
 It seems, that the risk for different outcomes may vary for those on different NOACs 
compared to those on VKAs. Therefore, further research is required, using different 
NOACs, and observing a number of outcomes with their associated mortality and 
quality of life. The adherence to different anticoagulants and its impact on any 
beneficial or adverse effects can also be addressed in future studies. Although 
observational studies are more prone to selection bias than RCTs, well-designed 
observational studies can provide good generalizability to real-world practice.6, 31 The 
combination of evidence from RCTs and observational research should lead to clear 
clinical recommendations about specific drugs in different groups of patients, and 
ultimately result in more effective and safer prevention of thromboembolic events in 
patients with AF.  
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